Artemis Medicare’s 19.64% margin trails healthcare peer median
The consolidated quarter included Rs 31.44 cr of net profit, while management linked lower other income to funds deployed for expansion.
Filed 03 Aug 2026, 17:21 IST · after market close · Artemis Medicare Services Ltd (ARTEMISMED)
Key takeaways
- Artemis Medicare’s consolidated operating margin of 19.64% was 3.31 percentage points below the 22.95% median for 29 reported healthcare peers.
- Management said bed capacity is expected to expand to about 2,000 over the next three to five years.
- The company said other income of Rs 5.37 cr declined as IFC funds were used for expansion projects.
Price around the results
Operating profit converted into Rs 31.44 cr of net profit
In consolidated Q1FY27, operating profit of Rs 56.44 cr on revenue of Rs 287.32 cr translated into a 19.64% operating margin. Interest of Rs 6.46 cr and depreciation of Rs 12.73 cr reduced profit before tax to Rs 42.63 cr, while tax of Rs 11.19 cr left net profit at Rs 31.44 cr. Other income was Rs 5.37 cr, and management said the line declined as IFC funds were utilised for expansion projects.
Margin remains below the reported healthcare peer median
Artemis Medicare’s 19.64% operating margin was 3.31 percentage points below the 22.95% median among 29 healthcare companies that had reported the same quarter. It ranked 9th from the bottom in that peer set, placing its operating profitability below the sector comparison point.
Management outlines capacity expansion and AI initiatives
Management said bed capacity is expected to expand to about 2,000 over the next three to five years, providing the company’s stated long-term growth framework. The company also said it is using AI-enabled clinical and operational workflows to improve efficiency and patient outcomes. Management attributed the decline in other income to IFC funds being directed towards expansion projects.
Results were filed after market close
The consolidated results were filed after market close on 03 Aug 2026 at 17:21 IST. The stock’s post-results reaction is therefore not covered here.
Q1FY27 at a glance
Consolidated figures as filed with NSE — filed ahead of third-party databases, not yet independently cross-checked.
| Line item | Q1FY27 |
|---|---|
| Revenue | ₹287 cr |
| Other income | ₹5 cr |
| Expenses | ₹231 cr |
| Operating profit | ₹56 cr |
| Operating margin (%) | 19.64% |
| Interest | ₹6 cr |
| Depreciation | ₹13 cr |
| Profit before tax | ₹43 cr |
| Tax | ₹11 cr |
| Net profit | ₹31 cr |
| EPS (₹) | ₹1.98 |
Operating margin of 19.64% compares with a Healthcare sector median of 22.95% across 29 peers that have reported Q1FY27.
What management said
From the company’s own investor presentation. Each point is checked against the source document before it appears here.
Guidance & outlook
- Bed capacity is expected to expand to about 2,000 over the next three to five years.
New initiatives
- The company is using AI-enabled clinical and operational workflows to improve efficiency and patient outcomes.
Problems & risks
- Other income declined because IFC funds were utilised toward expansion projects.
What to watch
- The next-quarter consolidated operating margin relative to 19.64%.
- Reported bed-capacity progress against management’s stated plan for about 2,000 beds over three to five years.
- Whether other income remains affected by IFC-fund utilisation after Rs 5.37 cr in Q1FY27.